comparemela.com

Latest Breaking News On - Elizabetho day - Page 3 : comparemela.com

Olaris Partners with Thermo Fisher on Metabolomics Diagnostic Assay for Immune Response in Transplant Recipients

Framingham, MA (PRWEB) January 18, 2022 Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning for the discovery and

Olaris, Inc to Present Data Identifying Metabolic Biomarkers of Response in Early-Stage Breast Cancer Patients at the 2021 San Antonio Breast Cancer Symposium

Olaris Welcomes Dr Leonardo Rodrigues as VP of Artificial Intelligence and Machine Learning

Olaris Welcomes Dr. Leonardo Rodrigues as VP of Artificial Intelligence and Machine Learning Share Article Bringing expertise in precision medicine, Dr. Rodrigues will lead the acceleration of Olaris’ data strategy for the development of novel diagnostics. Dr. Leonardo Rodrigues, VP of AI and ML at Olaris “Olaris is uniquely positioned to usher in the next generation of precision medicine tools that directly impact patient care. Their leadership to go beyond genomics and focus on metabolomics is pushing the field of precision medicine forward. WALTHAM, Mass. (PRWEB) May 12, 2021 Olaris, Inc, a pioneering precision medicine company leveraging metabolomics and machine learning for the discovery and development of Biomarkers of Response (BoRs) to optimize treatments and patient outcomes has hired Dr. Leonardo Rodrigues as Vice President of Artificial Intelligence & Machine Learning.

Olaris, Inc Announces Presentation on Metabolic Biomarkers of Response in Advanced GIST at American Association for Cancer Research (AACR) 2021 Annual Meeting

Olaris, Inc. Announces Presentation on Metabolic Biomarkers of Response in Advanced GIST at American Association for Cancer Research (AACR) 2021 Annual Meeting Share Article Olaris to present new data on metabolic signatures predictive of overall survival and therapeutic response in advanced GIST at upcoming AACR Virtual Meeting This study is particularly exciting as we were able to demonstrate and validate in an independent set of patient samples that metabolite biomarkers either before treatment or during treatment can identify patients with favorable clinical outcomes.” - Dr. Elizabeth O’Day, CEO and Founder of Olaris WALTHAM, Mass. (PRWEB) April 09, 2021 Olaris, Inc, a precision medicine company leveraging metabolomics and machine learning for the discovery and development of Biomarkers of Response (BoRs) to optimize treatments and patient outcomes, is pleased to announce the company’s presentation on

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.